OptiBiotix has issued a commercial and scientific update, highlighting the significant progress made across its range of prebiotic ingredients and products. The update further demonstrates OptiBiotix' ability to grow its product range, expand applications for existing products and extend its reach into new territories. OptiBiotix, is also conducting further clinical work to increase the body of evidence supporting its products to help drive future growth. We maintain our Buy rating.
21 Jul 2022
Cenkos: OptiBiotix Health Plc -- Commercial and Scientific Update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: OptiBiotix Health Plc -- Commercial and Scientific Update
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
21 Jul 2022 -
Author:
Cavendish Research -
Pages:
10
OptiBiotix has issued a commercial and scientific update, highlighting the significant progress made across its range of prebiotic ingredients and products. The update further demonstrates OptiBiotix' ability to grow its product range, expand applications for existing products and extend its reach into new territories. OptiBiotix, is also conducting further clinical work to increase the body of evidence supporting its products to help drive future growth. We maintain our Buy rating.